Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 73 results found. Search for [ bharat biotech covaxin phase 3 results ]

Results 40 to 60 of 73
BusinessToday.In
November 23, 2020
Coronavirus vaccine update: Adar Poonawalla, the CEO of Serum Institute had recently said that his company might sell a two-shot COVID-19 vaccine for around Rs 500-600 for the general public


BusinessToday.In
November 22, 2020
Bharat Biotech has started the phase- 3 trial of its potential COVID-19 vaccine, involving 26,000 volunteers this month across 25 centres in the country, including Hyderabad, Goa, Nagpur, Bhubaneswar, and Aligarh


BusinessToday.In
November 21, 2020
Bharat Biotech, the developer of India's indigenous vaccine Covaxin, has said that it is planning to enrol about 2,000 participants each in metros for Phase-3 trials of its COVID-19 vaccine that began earlier this week


Reuters
November 17, 2020
The Hyderabad-based firm initiated phase I and phase II trials of its vaccine candidate after getting the green signal from the Drugs Controller General of India


BusinessToday.In
November 11, 2020
Coronavirus vaccine: India will focus on these two vaccines as they are being tested on the Indian population and hence has a major advantage over other potential candidates


BusinessToday.In
November 7, 2020
India may concentrate its efforts on Bharat Biotech's Covaxin as AstraZeneca's COVID-19 vaccine deliveries may be delayed. The months of November and December could be critical in terms of vaccine availability as a number of companies are likely to publish late-stage trial data


BusinessToday.In
November 5, 2020
Coronavirus vaccine update: Data compiled by Duke Global Health Innovation Center said that India has pre-ordered 600 million doses of coronavirus vaccine and is now in the process of negotiation for additional 1 billion doses


BusinessToday.In
November 3, 2020
German biotech firm CureVac has revealed its vaccine candidate has triggered an immune response during its phase 1 trials. The UK government has also started the process of the rolling review of AstraZeneca's candidate


BusinessToday.In
October 26, 2020
Coronavirus vaccine: The pharma company plans to start late-stage trials of the vaccine candidate next month. Over 26,000 candidates would be monitored for the vaccine candidate's efficacy


BusinessToday.In
October 23, 2020
Covaxin, the coronavirus vaccine being developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), is expected to be at least 60 per cent effective


BusinessToday.In
October 22, 2020
Bharat Biotech Phase 3 trials: The volunteers would be given two doses of the experimental vaccine in a gap of 28 days


BusinessToday.In
October 14, 2020
Coronavirus vaccine update: Bharat Biotech is ready to start Covaxin's Phase 3 trail to test the vaccine on about 28,500 volunteers


BusinessToday.In
October 14, 2020
Coronavirus vaccine update: Biopharma company Epygen Biotech with operations in Mumbai and Dubai is planning to launch an affordable COVID-19 vaccine with an aim to roll out 500 million doses within six months


BusinessToday.In
October 9, 2020
Bharat Biotech vaccine: The subject expert committee that discussed the matter in a meeting on October 5 has asked the company to resubmit the protocol and clarify the definition of asymptomatic


BusinessToday.In
October 1, 2020
Coronavirus vaccine update: In India, there are three COVID-19 vaccines under human trials--Bharat Biotech's COVAXIN, Oxford's COVDSHIELD, and Zydus Cadila's ZyCoV-D. Serum Institute has already begun a phase-3 trial of Oxford vaccine candidates at 17 sites


BusinessToday.In
September 12, 2020
Bharat Biotech says its vaccine candidate was found to generate \"robust immune responses\", thus preventing infection and disease in primates upon high amounts of exposure to live SARS-CoV-2 virus


BusinessToday.In
August 22, 2020
Bharat Biotech has received nod to conduct the Phase I and II clinical trial of its COVID-19 vaccine 'Covaxin' through intradermal route, which is just under the skin


BusinessToday.In
August 9, 2020
Coronavirus vaccine update: The pandemic is putting pressure on the company to come out with a vaccine quickly, but we cannot rush as safety and quality are paramount, says Krishna M Ella


BusinessToday.In
August 4, 2020
Coronavirus vaccine update: Jeevan Rekha Hospital was among the 12 facilities selected by the ICMR to conduct human trials of Covaxin


Joe C Mathew
August 3, 2020
Indian vaccine manufacturers are waiting for a vaccination plan from the government so that they can set aside stocks of vaccines when they are approved for production


PAGES 3 OF 4  1234